Assessment of Coronary Plaque Composition
Completed · Phase 1
Conditions studied: Coronary Atherosclerosis, Endothelial Dysfunction, Coronary Small Vessel Disease
In brief
The investigators' hypothesis is that local activation of the endogenous Lipoprotein-associated phospholipase A2 (Lp-PLA2) plays an integral role in early atherosclerosis, and contributes to the mechanism of coronary endothelial dysfunction and to the structural and mechanical properties that characterize plaque vulnerability. Thus, this study will characterize prospectively the correlation between the functional and structural vascular wall properties, and the activity of the Lp-PLA2 pathway.
Key facts
- Study ID
- NCT01581632
- Run by
- Mayo Clinic
- People needed
- 39
- Starts
- 2010-01-01
- Expected to finish
- 2015-05-01
- Last updated by the study team
- 2019-03-05
Who can join
Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- patients age > 18 years and < 85 years
- referred to our cardiac catheterization laboratory for coronary vasomotion testing- subsequently found to have coronary endothelial dysfunction.
You may not qualify if…
- heart failure ejection fraction <40%,
- unstable angina
- myocardial infarction or angioplasty within 6 months prior to entry into the study
- use of investigational agents within 1 month of entry into the study
- patients who require treatment with positive inotropic agents other than digoxin during the study
- patients with cerebrovascular accident within 6 months prior to entry the study
- significant endocrine, hepatic or renal, disorders, local or systemic infectious disease within 4 weeks prior to entry into study
- pregnancy or lactation
- mental instability
Where it is running
- Mayo Clinic — Rochester, Minnesota, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.